Bard Financial Services, Inc. Dexcom Inc Transaction History

Bard Financial Services, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$75.49 - $124.16 $128,332 - $211,072	1,700 New	1,700 $210,000
Q1 2023 Apr 26, 2023	SELL	$104.0 - $122.92 $23,400 - $27,657	-225 Reduced 10.11%	2,000 $232,000
Q4 2022 Jan 25, 2023	BUY	$84.98 - $122.67 $189,080 - $272,940	2,225 New	2,225 $252,000
Q2 2022 Jul 06, 2022	SELL	$67.99 - $132.89 $37,394 - $73,089	-550 Closed	0 $0
Q4 2021 Jan 24, 2022	SELL	$129.87 - $162.82 $3,246 - $4,070	-25 Reduced 4.35%	550 $295,000
Q3 2021 Oct 15, 2021	SELL	$106.71 - $143.18 $5,335 - $7,159	-50 Reduced 8.0%	575 $314,000
Q4 2020 Mar 26, 2021	BUY	$78.0 - $104.5 $48,750 - $65,312	625 New	625 $231,000

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Bard Financial Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Bard Financial Services, Inc. with notifications on news.